CA2185457A1 - Use of nitric oxide-releasing polymers to treat restenosis and related disorders - Google Patents
Use of nitric oxide-releasing polymers to treat restenosis and related disordersInfo
- Publication number
- CA2185457A1 CA2185457A1 CA002185457A CA2185457A CA2185457A1 CA 2185457 A1 CA2185457 A1 CA 2185457A1 CA 002185457 A CA002185457 A CA 002185457A CA 2185457 A CA2185457 A CA 2185457A CA 2185457 A1 CA2185457 A1 CA 2185457A1
- Authority
- CA
- Canada
- Prior art keywords
- nitric oxide
- releasing
- related disorders
- delivery means
- restenosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F8/00—Chemical modification by after-treatment
- C08F8/30—Introducing nitrogen atoms or nitrogen-containing groups
- C08F8/32—Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polyethers (AREA)
Abstract
Methods of amelioration, treatment and prevention for restenosis and related disorders are provided. Methods involve the administration of nitric oxide by a nitric oxide delivery means comprising a restenosis-ameliorating or therapeutically/prophylactically effective amount of a polymer to which is bound a nitric oxide-releasing N2O2- functional group or a compound comprising a nitric oxide-releasing N2O2- functional group. Also provided are nitric oxide delivery means comprising such nitric oxide-releasing polymers or compounds for use in such methods. Preferably, the delivery means is coated with a nitric oxide-releasing polymer, which may be biodegradable, and enables the controllable and predictable release of NO to a given site in such a manner that effective ameliorating, prophylactic or therapeutic dosing is realized.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US214,372 | 1994-03-17 | ||
US08/214,372 US5650447A (en) | 1992-08-24 | 1994-03-17 | Nitric oxide-releasing polymers to treat restenosis and related disorders |
PCT/US1995/003040 WO1995024908A1 (en) | 1994-03-17 | 1995-03-09 | Use of nitric oxide-releasing polymers to treat restenosis and related disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2185457A1 true CA2185457A1 (en) | 1995-09-21 |
CA2185457C CA2185457C (en) | 2004-05-25 |
Family
ID=22798839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002185457A Expired - Fee Related CA2185457C (en) | 1994-03-17 | 1995-03-09 | Use of nitric oxide-releasing polymers to treat restenosis and related disorders |
Country Status (11)
Country | Link |
---|---|
US (1) | US5650447A (en) |
EP (1) | EP0752866B1 (en) |
JP (1) | JPH10502905A (en) |
AT (1) | ATE218352T1 (en) |
AU (1) | AU698525B2 (en) |
CA (1) | CA2185457C (en) |
DE (1) | DE69526934T2 (en) |
DK (1) | DK0752866T3 (en) |
ES (1) | ES2177637T3 (en) |
PT (1) | PT752866E (en) |
WO (1) | WO1995024908A1 (en) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5632981A (en) * | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US6255277B1 (en) | 1993-09-17 | 2001-07-03 | Brigham And Women's Hospital | Localized use of nitric oxide-adducts to prevent internal tissue damage |
US5681278A (en) * | 1994-06-23 | 1997-10-28 | Cormedics Corp. | Coronary vasculature treatment method |
GB9423868D0 (en) * | 1994-11-25 | 1995-01-11 | Wellcome Found | Compounds for use in medicine |
CN1160115C (en) * | 1994-12-12 | 2004-08-04 | 奥默罗斯公司 | Irrigation solution and method for inhibition of pain, inflammation |
US6063407A (en) * | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US20050152950A1 (en) * | 1995-11-13 | 2005-07-14 | Saffran Bruce N. | Method and apparatus for macromolecular delivery using a coated membrane |
US5770645A (en) * | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
US6232434B1 (en) | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
WO1998008496A1 (en) * | 1996-08-27 | 1998-03-05 | The University Of Akron | Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use |
US6372796B1 (en) * | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
US5994444A (en) * | 1997-10-16 | 1999-11-30 | Medtronic, Inc. | Polymeric material that releases nitric oxide |
US6221425B1 (en) | 1998-01-30 | 2001-04-24 | Advanced Cardiovascular Systems, Inc. | Lubricious hydrophilic coating for an intracorporeal medical device |
US20040254635A1 (en) | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US5962520A (en) * | 1998-04-02 | 1999-10-05 | The University Of Akron | Hydrolytically unstable, biocompatible polymer |
US6207855B1 (en) | 1998-06-23 | 2001-03-27 | Duke University Medical Center | Stable no-delivering compounds |
US20040043068A1 (en) * | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
AU5144600A (en) * | 1999-05-21 | 2000-12-12 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an embolizing composition |
US6645167B1 (en) | 1999-05-21 | 2003-11-11 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an embolizing composition |
US7018365B2 (en) | 1999-05-21 | 2006-03-28 | Micro Therapeutics, Inc. | Threaded syringe with quick stop |
EP1207811A4 (en) * | 1999-08-04 | 2007-03-07 | Bard Inc C R | Nitric oxide releasing medical devices |
US20040102804A1 (en) * | 1999-08-10 | 2004-05-27 | Chin Albert K. | Apparatus and methods for endoscopic surgical procedures |
US7288096B2 (en) | 2003-01-17 | 2007-10-30 | Origin Medsystems, Inc. | Apparatus for placement of cardiac defibrillator and pacer |
US7597698B2 (en) * | 1999-08-10 | 2009-10-06 | Maquet Cardiovascular Llc | Apparatus and method for endoscopic encirclement of pulmonary veins for epicardial ablation |
US20030187461A1 (en) * | 1999-08-10 | 2003-10-02 | Chin Albert K. | Releasable guide and method for endoscopic cardiac lead placement |
US7526342B2 (en) * | 1999-08-10 | 2009-04-28 | Maquet Cardiovascular Llc | Apparatus for endoscopic cardiac mapping and lead placement |
US7398781B1 (en) * | 1999-08-10 | 2008-07-15 | Maquet Cardiovascular, Llc | Method for subxiphoid endoscopic access |
US6569082B1 (en) | 1999-08-10 | 2003-05-27 | Origin Medsystems, Inc. | Apparatus and methods for cardiac restraint |
US20060287574A1 (en) * | 1999-08-25 | 2006-12-21 | Chin Albert K | Longitudinal dilator |
US6660260B1 (en) | 1999-09-21 | 2003-12-09 | Mayo Foundation For Medical Education And Research | Bioprosthetic heart valves |
US6730313B2 (en) | 2000-01-25 | 2004-05-04 | Edwards Lifesciences Corporation | Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia |
US6270779B1 (en) * | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
CA2414941C (en) | 2000-08-11 | 2010-12-14 | David R. Whitlock | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
US20050043506A1 (en) * | 2000-09-27 | 2005-02-24 | Michigan Biotechnology Institute | Polyamide materials based on unsaturated carboxylic acids and amines |
US6797743B2 (en) * | 2000-09-27 | 2004-09-28 | Michigan Biotechnology Institute | Antimicrobial polymer |
JP2004515271A (en) * | 2000-10-11 | 2004-05-27 | マイクロ・セラピューティクス・インコーポレーテッド | How to treat aneurysms |
DE20122506U1 (en) | 2000-10-16 | 2005-12-08 | Conor Medsystems, Inc., Menlo Park | Expandable medical device for delivering a beneficial agent |
US7049308B2 (en) * | 2000-10-26 | 2006-05-23 | Duke University | C-nitroso compounds and use thereof |
US6565601B2 (en) | 2000-11-15 | 2003-05-20 | Micro Therapeutics, Inc. | Methods for vascular reconstruction of diseased arteries |
AU2002231175A1 (en) * | 2000-12-27 | 2002-07-08 | Focal, Inc. | Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart |
US20040073294A1 (en) | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
JP2004528337A (en) | 2001-05-02 | 2004-09-16 | ニトロメド インコーポレーテッド | Nitrosated and nitrosylated nebivolol, and metabolites, compositions, and methods of use |
EP1436018A1 (en) * | 2001-09-26 | 2004-07-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Nitric oxide-releasing coated medical devices and method of preparing same |
US6703046B2 (en) * | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
AU2003222569A1 (en) * | 2002-01-11 | 2003-07-24 | Whitlock, David R. | Compositions including ammonia oxidizing bacteria and methods of using same |
US6939554B2 (en) * | 2002-02-05 | 2005-09-06 | Michigan Biotechnology Institute | Antimicrobial polymer |
TW200307734A (en) | 2002-03-20 | 2003-12-16 | Michigan Biotech Inst | Conductive polymer-based material |
CA2480033C (en) * | 2002-03-21 | 2011-05-10 | The University Of Utah Research Foundation | In vivo use of glutathionone s-transferase activated nitric oxide donors |
CA2485167A1 (en) * | 2002-05-07 | 2003-11-20 | The Government Of The United States Of America | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same |
WO2003095623A2 (en) * | 2002-05-10 | 2003-11-20 | The Trustees Of Columbia University In The City Of New York | Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof |
JP2005534485A (en) | 2002-08-02 | 2005-11-17 | アメリカ合衆国 | Cross-linked nitric oxide-releasing polyamine-coated substrate, composition containing it and method for its production |
US6951902B2 (en) * | 2002-08-16 | 2005-10-04 | Michigan Biotechnology Institute | Two dimensional polymer that generates nitric oxide |
EP1610823B1 (en) | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
EP1624953B1 (en) * | 2003-04-23 | 2018-12-19 | The University of Akron | Sequestered reactive materials |
EA014704B1 (en) * | 2003-07-03 | 2011-02-28 | Ти Юниверсити Корт Оф Ти Юниверсити Оф Ст Эндрюс | Fully or partially dehydrated zeolite material for dosing of nitric oxide |
JP2007502831A (en) * | 2003-08-20 | 2007-02-15 | ニトロメッド インコーポレーティッド | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
AU2004270161A1 (en) * | 2003-08-28 | 2005-03-17 | Nicox S.A. | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use |
US7785653B2 (en) | 2003-09-22 | 2010-08-31 | Innovational Holdings Llc | Method and apparatus for loading a beneficial agent into an expandable medical device |
US7379190B2 (en) * | 2004-01-05 | 2008-05-27 | Zygo Corporation | Stage alignment in lithography tools |
JP2007526911A (en) * | 2004-01-22 | 2007-09-20 | ザ ユニバーシティ オブ アクロン | Polymer NO Donor Predrug Nanofiber Coating for Medical Devices and Therapy |
CA2554716A1 (en) * | 2004-01-22 | 2005-08-04 | Nitromed, Inc. | Nitrosated and/or nitrosylated compounds, compositions and methods of use |
US20050165452A1 (en) * | 2004-01-28 | 2005-07-28 | Medtronic, Inc. | Antithrombogenic medical device |
AU2005215970A1 (en) * | 2004-02-09 | 2005-09-09 | Noxilizer, Inc. | Nitric oxide-releasing molecules |
AU2005239995A1 (en) * | 2004-03-31 | 2005-11-17 | Nitromed, Inc. | Methods for treating blood disorders with nitric oxide donor compounds |
US20060039950A1 (en) * | 2004-08-23 | 2006-02-23 | Zhengrong Zhou | Multi-functional biocompatible coatings for intravascular devices |
US7968664B2 (en) * | 2004-09-27 | 2011-06-28 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing diazeniumdiolated acrylonitrile-based polymers, and compositions, medical devices, and uses thereof |
WO2006041855A2 (en) | 2004-10-04 | 2006-04-20 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
AU2005304770A1 (en) * | 2004-11-08 | 2006-05-18 | Nicox S.A. | Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders |
US9050393B2 (en) | 2005-02-08 | 2015-06-09 | Bruce N. Saffran | Medical devices and methods for modulation of physiology using device-based surface chemistry |
EP1690532A1 (en) * | 2005-02-11 | 2006-08-16 | NOLabs AB | Device for gastric treatment and manufacturing process for the same |
WO2006084914A2 (en) * | 2005-02-11 | 2006-08-17 | Nolabs Ab | Device for gastric treatment and manufacturing process for the same |
CA2594407C (en) * | 2005-02-11 | 2014-06-10 | Nolabs Ab | Device method, and use for treatment of neuropathy involving nitric oxide |
AU2006218766A1 (en) * | 2005-02-28 | 2006-09-08 | Nicox S.A. | Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use |
JP2008533031A (en) * | 2005-03-09 | 2008-08-21 | ニトロメッド インコーポレーティッド | Organic nitric oxide enhancing salts, compositions and methods of use of angiotensin II antagonists |
EP1865770A4 (en) * | 2005-04-07 | 2010-12-29 | Nitromed Inc | The genetic risk assessment in heart failure: impact of the genetic variation of nos3 |
US20090048219A1 (en) * | 2005-05-23 | 2009-02-19 | Nitromed Inc. | Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use |
US20090214618A1 (en) | 2005-05-27 | 2009-08-27 | Schoenfisch Mark H | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US20080241208A1 (en) * | 2005-06-30 | 2008-10-02 | Charles Shanley | Methods, Compositions and Devices For Promoting Anglogenesis |
CA2613106A1 (en) * | 2005-06-30 | 2007-01-11 | Mc3, Inc. | Analyte sensors and compositions for use therein |
JP2008544820A (en) * | 2005-06-30 | 2008-12-11 | エムシー3, インコーポレイテッド | Nitric oxide coating for medical devices |
WO2007016677A2 (en) | 2005-08-02 | 2007-02-08 | Nitromed, Inc. | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
JP2009505727A (en) * | 2005-08-25 | 2009-02-12 | メドトロニック ヴァスキュラー インコーポレイテッド | Nitric oxide releasing biodegradable polymers useful as medical devices and their coatings |
US20070053952A1 (en) * | 2005-09-07 | 2007-03-08 | Medtronic Vascular, Inc. | Nitric oxide-releasing polymers derived from modified polymers |
EP1945030A4 (en) * | 2005-10-04 | 2009-10-21 | Nitromed Inc | The genetic risk assessment in heart failure: impact of genetic variation of beta 1 adrenergic receptor gly389arg polymorphism |
EP1942942A2 (en) * | 2005-10-31 | 2008-07-16 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates |
EP1954685A4 (en) * | 2005-11-16 | 2009-11-11 | Nitromed Inc | Furoxan compounds, compositions and methods of use |
US20090287072A1 (en) * | 2005-12-02 | 2009-11-19 | The Regents Of The University Of Michigan | Polymer compositions, coatings and devices, and methods of making and using the same |
CA2632683A1 (en) * | 2005-12-06 | 2007-06-14 | Amulet Pharmaceuticals, Inc. | Nitric oxide-releasing polymers |
EP1968584A2 (en) * | 2005-12-20 | 2008-09-17 | Nitromed, Inc. | Nitric oxide enhancing glutamic acid compounds, compositions and methods of use |
AU2007243765A1 (en) * | 2006-03-29 | 2007-11-08 | Nicox S.A. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
US8241619B2 (en) * | 2006-05-15 | 2012-08-14 | Medtronic Vascular, Inc. | Hindered amine nitric oxide donating polymers for coating medical devices |
US7811600B2 (en) * | 2007-03-08 | 2010-10-12 | Medtronic Vascular, Inc. | Nitric oxide donating medical devices and methods of making same |
US8273828B2 (en) | 2007-07-24 | 2012-09-25 | Medtronic Vascular, Inc. | Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation |
US20100316622A1 (en) * | 2007-11-02 | 2010-12-16 | University Of Miami | Diagnosis and treatment of cardiac disorders |
WO2009064861A2 (en) * | 2007-11-13 | 2009-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof |
US20090170933A1 (en) * | 2007-12-26 | 2009-07-02 | Cook Incorporated | Method for removing a medical device from a spasmodic constriction in a bodily passageway |
US20090222088A1 (en) * | 2008-02-29 | 2009-09-03 | Medtronic Vascular, Inc. | Secondary Amine Containing Nitric Oxide Releasing Polymer Composition |
CA2717867C (en) * | 2008-03-07 | 2017-05-30 | Paul J. Shami | Activated nitric oxide donors and methods of making and using thereof |
US20090232868A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Nitric Oxide Releasing Polymer Composition |
US20090232863A1 (en) * | 2008-03-17 | 2009-09-17 | Medtronic Vascular, Inc. | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers |
US8841440B2 (en) | 2008-04-01 | 2014-09-23 | Cornell University | Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof |
US8158187B2 (en) * | 2008-12-19 | 2012-04-17 | Medtronic Vascular, Inc. | Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices |
US8709465B2 (en) * | 2009-04-13 | 2014-04-29 | Medtronic Vascular, Inc. | Diazeniumdiolated phosphorylcholine polymers for nitric oxide release |
US9309347B2 (en) | 2009-05-20 | 2016-04-12 | Biomedical, Inc. | Bioresorbable thermoset polyester/urethane elastomers |
US20110319987A1 (en) | 2009-05-20 | 2011-12-29 | Arsenal Medical | Medical implant |
US9265633B2 (en) | 2009-05-20 | 2016-02-23 | 480 Biomedical, Inc. | Drug-eluting medical implants |
US8137396B2 (en) * | 2009-05-20 | 2012-03-20 | 480 Biomedical, Inc | Medical implant |
US8888840B2 (en) * | 2009-05-20 | 2014-11-18 | Boston Scientific Scimed, Inc. | Drug eluting medical implant |
US8992601B2 (en) | 2009-05-20 | 2015-03-31 | 480 Biomedical, Inc. | Medical implants |
LT2440239T (en) | 2009-06-09 | 2017-12-11 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
EP4249001A3 (en) | 2009-08-21 | 2023-11-29 | Novan, Inc. | Topical gels |
WO2011022680A2 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US8372133B2 (en) * | 2009-10-05 | 2013-02-12 | 480 Biomedical, Inc. | Polymeric implant delivery system |
US20110301299A1 (en) | 2010-06-08 | 2011-12-08 | Medtronic Vascular, Inc. | Medical Devices and Polymers Therefor Having PTFE Surfaces Modified With Nitric Oxide-Releasing Polymers |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
US20150132345A1 (en) | 2011-05-09 | 2015-05-14 | Yossef Av-Gay | Nitric oxide-sequestering topical formulations |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
KR20230165365A (en) | 2014-04-15 | 2023-12-05 | 에이오바이오미 엘엘씨 | Ammonia-oxidizing nitrosomonas eutropha strain d23 |
RU2714313C2 (en) * | 2014-08-14 | 2020-02-14 | Ром Энд Хаас Компани | Polymer with released gas |
GB2540643B (en) | 2015-02-03 | 2019-11-06 | Univ Court Univ St Andrews | NO containing compositions |
WO2018067838A1 (en) | 2016-10-07 | 2018-04-12 | The University Of North Carolina At Chapel Hill | S-nitrosothiol-mediated hyperbranched polyesters |
CN110198959B (en) | 2017-01-03 | 2023-03-28 | 北卡罗米纳大学查佩尔希尔分校 | Nitric oxide releasing alginate as biodegradable antimicrobial scaffolds and related methods |
CA3055474A1 (en) | 2017-03-28 | 2018-10-04 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto |
EP3762039A4 (en) | 2018-03-06 | 2021-12-22 | The University of North Carolina at Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
CN113383019B (en) | 2018-12-28 | 2023-11-17 | 北卡罗来纳大学教堂山分校 | Nitric oxide releasing antimicrobial polymers and scaffolds made therefrom and methods relating thereto |
US20230140515A1 (en) * | 2021-11-03 | 2023-05-04 | Baxter International Inc. | Nitric oxide donors for use in surgical recovery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL151996B (en) * | 1971-04-15 | 1977-01-17 | Snam Progetti | PROCESS FOR THE PREPARATION OF MODIFIED POLYMERS. |
US4954526A (en) * | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
US5039705A (en) * | 1989-09-15 | 1991-08-13 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5208233A (en) * | 1989-09-15 | 1993-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof |
US5212204A (en) * | 1989-10-18 | 1993-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Antihypertensive compositions and use thereof |
US5155137A (en) * | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5185376A (en) * | 1991-09-24 | 1993-02-09 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof |
US5219710A (en) * | 1991-11-25 | 1993-06-15 | Allied-Signal Inc. | Polymeric nitrones having a styrene-derived backbone chain |
-
1994
- 1994-03-17 US US08/214,372 patent/US5650447A/en not_active Expired - Fee Related
-
1995
- 1995-03-09 AU AU19889/95A patent/AU698525B2/en not_active Ceased
- 1995-03-09 PT PT95912871T patent/PT752866E/en unknown
- 1995-03-09 EP EP95912871A patent/EP0752866B1/en not_active Expired - Lifetime
- 1995-03-09 CA CA002185457A patent/CA2185457C/en not_active Expired - Fee Related
- 1995-03-09 DE DE69526934T patent/DE69526934T2/en not_active Expired - Fee Related
- 1995-03-09 DK DK95912871T patent/DK0752866T3/en active
- 1995-03-09 ES ES95912871T patent/ES2177637T3/en not_active Expired - Lifetime
- 1995-03-09 AT AT95912871T patent/ATE218352T1/en not_active IP Right Cessation
- 1995-03-09 WO PCT/US1995/003040 patent/WO1995024908A1/en active IP Right Grant
- 1995-03-09 JP JP7524103A patent/JPH10502905A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69526934T2 (en) | 2003-01-02 |
AU698525B2 (en) | 1998-10-29 |
AU1988995A (en) | 1995-10-03 |
DK0752866T3 (en) | 2002-09-16 |
US5650447A (en) | 1997-07-22 |
CA2185457C (en) | 2004-05-25 |
ATE218352T1 (en) | 2002-06-15 |
JPH10502905A (en) | 1998-03-17 |
PT752866E (en) | 2002-11-29 |
EP0752866B1 (en) | 2002-06-05 |
EP0752866A1 (en) | 1997-01-15 |
DE69526934D1 (en) | 2002-07-11 |
WO1995024908A1 (en) | 1995-09-21 |
ES2177637T3 (en) | 2002-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2185457A1 (en) | Use of nitric oxide-releasing polymers to treat restenosis and related disorders | |
WO2002069963A3 (en) | Compositions comprising ferulic acid, caffeic acid, tannic acid or ellagic acid and their use for the preparation of a medicament for the treatment of dermatological disorders | |
CA2296336A1 (en) | Analgesic compositions comprising anti-epileptic compounds and methods of using same | |
WO1999025395A3 (en) | Improved wound dressing device | |
CA2111836A1 (en) | Spin-trapping pharmaceutical compositions and methods for use thereof | |
CA2214097A1 (en) | Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx | |
CA2130805A1 (en) | Use of mannose phosphates for the treatment of fibrotic disorders | |
EP1688143A3 (en) | Niacin-containing substained-release tablets and kits | |
CA2274074A1 (en) | Novel compounds with analgesic effect | |
AU2002236470A1 (en) | Uses for medical devices having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders | |
IL126589A (en) | 2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficits | |
CA2337750A1 (en) | Therapeutic or cosmetic compositions containing dimeric or polymeric forms of hydroxyacids, and their therapeutic use | |
CA2289717A1 (en) | Novel therapy for constipation | |
CA2189916A1 (en) | A new regime for paclitaxel in kaposi's sarcoma patients | |
CA2143413A1 (en) | Local Drug Delivery Film, for Periodontal Treatment | |
CA2154103A1 (en) | Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain | |
CA2139385A1 (en) | Products containing g-csf and tnf binding protein | |
CA2108963A1 (en) | Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia | |
WO2000069255A8 (en) | Anti-inflammatory therapy for inflammatory mediated infection | |
CA2156481A1 (en) | 5-ht2 receptor antagonist compositions useful in treating venous conditions | |
CA2282279A1 (en) | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions | |
CA2131991A1 (en) | Treatment of Migraine | |
AU1546101A (en) | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders | |
EP1806144A3 (en) | Use of SARP-1 for the treatment and/or prevention of scleroderma | |
HK1015692A1 (en) | Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |